Page last updated: 2024-11-01

ns 1619 and Pulmonary Hypertension

ns 1619 has been researched along with Pulmonary Hypertension in 2 studies

NS 1619: structure given in first source
NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Revermann, M1
Neofitidou, S1
Kirschning, T1
Schloss, M1
Brandes, RP1
Hofstetter, C1
McCullough, DJ1
Vang, A1
Choudhary, G1

Other Studies

2 other studies available for ns 1619 and Pulmonary Hypertension

ArticleYear
Inhalation of the BK(Ca)-opener NS1619 attenuates right ventricular pressure and improves oxygenation in the rat monocrotaline model of pulmonary hypertension.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Administration, Inhalation; Animals; Becaplermin; Benzimidazoles; Blotting, Western; Cell Proliferat

2014
NS1619-induced vasodilation is enhanced and differentially mediated in chronically hypoxic lungs.
    Lung, 2014, Volume: 192, Issue:5

    Topics: Animals; Antihypertensive Agents; Benzimidazoles; Calcium Channels, L-Type; Chronic Disease; Disease

2014